Patents by Inventor Mark Jeroen KWAKKENBOS

Mark Jeroen KWAKKENBOS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160194382
    Abstract: The invention provides means and methods for modulating the occurrence of somatic hypermutations in antibody producing plasmablast-like B-cells.
    Type: Application
    Filed: February 19, 2016
    Publication date: July 7, 2016
    Inventors: Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Hergen SPITS, Adrianus Quirinus BAKKER
  • Publication number: 20160168232
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Application
    Filed: March 5, 2013
    Publication date: June 16, 2016
    Inventors: Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Eric J. BROWN, John Hiroshi MORISAKI, Wouter L.W. HAZENBOS, Sanjeev MARIATHASAN, Kimberly KAJIHARA, Yi XIA
  • Patent number: 9321831
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: April 26, 2016
    Assignee: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • Publication number: 20160096881
    Abstract: The invention provides means and methods for producing high-affinity antibodies against an antigen of interest, usually stable B-cell cultures.
    Type: Application
    Filed: December 2, 2015
    Publication date: April 7, 2016
    Inventors: Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Hergen SPITS, Adrianus Quirinus BAKKER, Koen WAGNER
  • Patent number: 9266943
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: February 23, 2016
    Assignees: Genentech, Inc., AIMM Therapeutics B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • Publication number: 20150376266
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Application
    Filed: June 2, 2015
    Publication date: December 31, 2015
    Inventors: Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Eric J. BROWN, John Hiroshi MORISAKI, Wouter L.W. HAZENBOS, Sanjeev MARIATHASAN, Kimberly KAJIHARA, Yi XIA
  • Patent number: 9206247
    Abstract: Described are means and methods for producing high-affinity antibodies against an antigen of interest, using stable B-cell cultures.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: December 8, 2015
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Hergen Spits, Adrianus Quirinus Bakker, Koen Wagner
  • Patent number: 9090677
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: July 28, 2015
    Assignee: Genentech, Inc.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • Publication number: 20150010566
    Abstract: The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for multiple influenza A virus subtypes. The invention further relates to the use of such antibodies for diagnosis of an influenza A virus infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of an influenza A virus infection.
    Type: Application
    Filed: December 3, 2012
    Publication date: January 8, 2015
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Arjen Quirinus Bakker
  • Publication number: 20140377279
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Application
    Filed: September 13, 2013
    Publication date: December 25, 2014
    Applicant: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • Publication number: 20140235828
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Application
    Filed: December 11, 2013
    Publication date: August 21, 2014
    Applicants: AIMM THERAPEUTICS B.V., GENENTECH, INC.
    Inventors: Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Eric J. BROWN, John Hiroshi MORISAKI, Wouter L.W. HAZENBOS, Sanjeev MARIATHASAN, Kimberly KAJIHARA, Yi XIA
  • Publication number: 20140072575
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Application
    Filed: September 13, 2013
    Publication date: March 13, 2014
    Applicant: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • Patent number: 8617556
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: December 31, 2013
    Assignees: Genentech, Inc., AIMM Therapeutics B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • Publication number: 20130331552
    Abstract: Described are means and methods for producing high-affinity antibodies against an antigen of interest, using stable B-cell cultures.
    Type: Application
    Filed: December 2, 2011
    Publication date: December 12, 2013
    Applicant: AIMM Therapeutics B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Hergen Spits, Adrianus Quirinus Bakker, Koen Wagner
  • Publication number: 20130261293
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Application
    Filed: March 5, 2013
    Publication date: October 3, 2013
    Applicant: GENENTECH, INC.
    Inventors: Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Eric J. BROWN, John Hiroshi MORISAKI, Wouter L.W. HAZENBOS, Sanjeev MARIATHASAN, Kimberly KAJIHARA, Yi XIA
  • Publication number: 20130253175
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Application
    Filed: March 5, 2013
    Publication date: September 26, 2013
    Applicant: GENENTECH, INC.
    Inventors: Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Eric J. BROWN, John Hiroshi MORISAKI, Wouter L.W. HAZENBOS, Sanjeev MARIATHASAN, Kimberly KAJIHARA, Yi XIA